A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Hepatic Function ◽

Trastuzumab Emtansine ◽

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis

Annals of Oncology ◽

10.1093/annonc/mdw337.21 ◽

2016 ◽

Vol 27 ◽

pp. iv65

Author(s):

L. Pizzuti ◽

I. Sperduti ◽

A. Michelotti ◽

C. Omarini ◽

T. Gamucci ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment

Medicine ◽

10.1097/md.0000000000022331 ◽

2020 ◽

Vol 99 (38) ◽

pp. e22331

Author(s):

Rurina Watanuki ◽

Akihiko Shimomura ◽

Shu Yazaki ◽

Shoko Noda-Narita ◽

Hitomi Sumiyoshi-Okuma ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Survival Outcomes ◽

Trastuzumab Emtansine ◽

Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer

American Journal of Health-System Pharmacy ◽

10.2146/ajhp130342 ◽

2014 ◽

Vol 71 (7) ◽

pp. 537-548 ◽

Cited By ~ 4

Author(s):

K. C. Patel ◽

K. Hageman ◽

M. R. Cooper

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Human Epidermal Growth Factor ◽

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies

Therapeutic Advances in Medical Oncology ◽

10.1177/1758834012451205 ◽

2012 ◽

Vol 4 (5) ◽

pp. 235-245 ◽

Cited By ~ 14

Author(s):

Sara A. Hurvitz ◽

Reva Kakkar

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Human Epidermal Growth Factor ◽

Trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC): Results from a multicenter retrospective analysis

Annals of Oncology ◽

10.1093/annonc/mdw365.54 ◽

2016 ◽

Vol 27 ◽

pp. vi85

Author(s):

L. Pizzuti ◽

I. Sperduti ◽

A. Michelotti ◽

C. Omarini ◽

T. Gamucci ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

European Journal of Cancer ◽

10.1016/j.ejca.2021.05.025 ◽

2021 ◽

Vol 153 ◽

pp. 223-233

Author(s):

Volkmar Mueller ◽

Andrew Wardley ◽

Elisavet Paplomata ◽

Erika Hamilton ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India

ecancermedicalscience ◽

10.3332/ecancer.2021.1207 ◽

2021 ◽

Vol 15 ◽

Author(s):

Anjana Joel ◽

Josh Thomas Georgy ◽

Divya Bala Thumaty ◽

Ajoy Oommen John ◽

Raju Titus Chacko ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Patterns Of Use ◽

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.09.007 ◽

2020 ◽

Vol 20 (2) ◽

pp. 160-167

Author(s):

John Smith ◽

Amy Irwin ◽

Lori Jensen ◽

Karen Tedesco ◽

Soamnauth Misir ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

Chromosome 17 Polysomy without Human Epidermal Growth Factor Receptor 2 Amplification Does Not Predict Response to Lapatinib Plus Paclitaxel Compared with Paclitaxel in Metastatic Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-1643 ◽

2010 ◽

Vol 16 (4) ◽

pp. 1281-1288 ◽

Cited By ~ 27

Author(s):

L. Downey ◽

R. B. Livingston ◽

M. Koehler ◽

M. Arbushites ◽

L. Williams ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Chromosome 17 ◽

Human Epidermal Growth Factor ◽

Efficacy and safety of bevacizumab in the treatment of human epidermal growth factor receptor type 2 negative metastatic breast cancer: About a large series in moroccan population

Indian Journal of Cancer ◽

10.4103/0019-509x.146779 ◽

2014 ◽

Vol 51 (3) ◽

pp. 272 ◽

Cited By ~ 1

Author(s):

N Majid ◽

S Boutayeb ◽

H Errihani

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Efficacy And Safety ◽